Figure 1
Flowchart of the NOPHO-AML 2004 protocol. High-risk patients were eligible for HSCT after completing 3 courses but before the last consolidation (HA2E). AIET indicates cytarabine 200 mg/m2 continuous infusion days 1-4, 6-thioguanine 100 mg/m2 bis in die (bid) days 1-4, etoposide 100 mg/m2 days 1-4, idarubicin 12 mg/m2 days 2, 4, and 6. AM indicates cytarabine 100 mg/m2 continuous infusion days 1-5, mitoxantrone 10 mg/m2 days 1-3. HA1M indicates cytarabine 1 g/m2 bid days 1-3, mitoxantrone 10 mg/m2 days 3-5. HA2E indicates cytarabine 2 g/m2 bid days 1-3, etoposide 100 mg/m2 days 2-5. HA3 indicates cytarabine 3 g/m2 bid days 1-3. GO indicates gemtuzumab ozogamicin 5 mg/m2 days 1 and 21.
